Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting Antivirals
Open Access
- 1 October 2020
- journal article
- conference paper
- Published by Elsevier BV in Transplantation Proceedings
- Vol. 52 (8), 2450-2453
- https://doi.org/10.1016/j.transproceed.2020.01.098
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Systematic review with meta‐analysis: effectiveness of direct‐acting antiviral treatment for hepatitis C in patients with hepatocellular carcinomaAlimentary Pharmacology & Therapeutics, 2019
- Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysisJournal of Hepatology, 2019
- Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct‐acting antiviralsJournal of Viral Hepatitis, 2018
- Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinomaJournal of Hepatology, 2017
- Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antiviralsJournal of Hepatology, 2017
- Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problemWorld Journal of Gastroenterology, 2014
- Validating posttransplant hepatocellular carcinoma recurrence data in the united network for organ sharing databaseLiver Transplantation, 2013
- Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients with Hepatitis CJournal of Gastrointestinal Cancer, 2010
- Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirinJournal of Hepatology, 2008
- Hepatocellular Carcinoma Is Associated With an Increased Risk of Hepatitis B Virus Recurrence After Liver TransplantationGastroenterology, 2008